Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 18, 2025Frontiers in ImmunologyOpen Access

Ruxolitinib and decitabine plus a busulfan–cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYujun WeiCentral South University of Forestry and TechnologySLSonghua LuanChinese PLA General HospitalLWLu WangWannan Medical College

Discussion

Loading...

Member takes

Implication

Investigational study shows reduced relapse in high-risk AML/MDS patients using ruxolitinib, decitabine, and mBu/Cy conditioning.

Key Points

  • The cumulative incidence of relapse was only 19.0% among patients treated with Rux-Dec-mBu/Cy after 2 years.
  • Cumulative 2-year overall survival was reported at 70.3%, indicating a promising outcome for high-risk AML/MDS patients.
  • Observational study design included 58 patients from May 2020 to July 2023, all experiencing acute myeloid leukemia or myelodysplastic syndromes.
  • These findings suggest Rux-Dec-mBu/Cy may improve overall prognosis while maintaining tolerability.

Cite This Study

Wei et al. (2025) studied this question.

synapsesocial.com/papers/68af453aad7bf08b1ead29d2https://doi.org/10.3389/fimmu.2025.1586512
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1[Chinese expert consensus on the diagnosis and treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation (2024)].2024 · 10 citations
  2. 2Molecular International Prognostic Scoring System for Myelodysplastic Syndromes2022 · 872 citations
  3. 3International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium2015 · 1,036 citations
  4. 4Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia2015 · 667 citations
  5. 5The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo2013 · 349 citations